Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 330 participants.

Also called NCT05203224

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 330 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05203224
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05203224. Allocation not applicable; no masking; primary purpose treatment. Start 2022-02-18 (actual); primary completion 2025-11-24 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)
Intervention (Drug)
Dornase Alfa
Lead sponsor
University of Melbourne (class: other)

Record details

Record id
cardio:ct-nct05203224
Content hash
c11133c70b2a0b1ad9ab5cf40403e013149193477bb286e3d7353d860b18ec03